MGB
CRSP icon

Mass General Brigham’s CRISPR Therapeutics CRSP Stock Holding History

Mass General Brigham’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,464
Closed -$1.05M – 8
2021
Q2 		$1.05M Buy
+6,464
New +$786K 0.26% 7

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Mass General Brigham's CRSP Position: Q3 2021 in Review

Mass General Brigham sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 6,464 shares — an estimated $1.05M sold.

Mass General Brigham first reported a position in CRSP in Q2 2021 and held it in 1 quarter. The position peaked at $1.05M in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Mass General Brigham reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Mass General Brigham sold 6,464 CRISPR Therapeutics shares in Q3 2021, an estimated $1.05M.
  • Mass General Brigham first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 1 quarter.
  • Mass General Brigham's CRISPR Therapeutics position peaked at $1.05M in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Mass General Brigham's 13F filing for Q3 2021, filed 8 Oct 2021.